Fecha de actualización: Octubre de 2017

 

Discovery
Click for more info Project Teaser


Indication
Target
CM-352 Bleeding
Disorders
Research Group
MMP10 & MMP3

 

CM-272 Cancer
AML & HCC
Research Group
DNMT & G9a

 

CM-414 Alzheimer’s Disease
Research Group
PDE5 & HDACs

 

CM-695 Stroke in
Atrial
Fibrillation
Research Group
HSP70

 

Apo-Insulin

Diabetes

Research Group

Insulin
Receptor

 

Sushi-IL15-
Apo
Oncolmmuno
Research Group
Receptor IL-15

 

CM-1349 Acute
intermittent porphyria
PBGD

 

CIRP-vaccine Oncolmmuno
Research Group
CD8 T cell simulation

 

Apo-
FGF19
Liver
regeneration
Research Group
FGF19 receptor

 

Target ID In vitro
Assays
Hit ID In vivo PoC
/ Lead id
ADMET / PK
Optimización
Preclinical Clinical
 
   
   
   
     
     
     
     
       
Partners
Licensed
IP


Allgen Therapeutics SL   ok
Epical BioSciences SL   ok
    ok
    ok
Undisclosed   ok
    ok
Undisclosed    
     
    ok
 


 

Early Discovery
Click for more info Project Teaser


Indication
Target
Viro Therapy Oncolmmuno
Research Group

Inmune response

 

CM-1215

Oncolmmuno

Research Group

Disruption Foxp3/ NFAT interaction

 

ELIRATRA

Oncolmmuno

Inmune response

 

CM-1129

Onco- immunology

Disruption Foxp3/ NFAT interaction

 

CM-825

Heart Failure

fibrosis

Research Group

Novel Target (undisclosed)

 

GPCR-X antagonist Alzheimers's Disease
Research Group
Novel Target (GPCR-undisclosed)

 

Drug Delivery Vectors Oncology
Research Group
Validated Target

 

CM-dvto2 Dravet Syndrome
Research Group
SCN1A

 

CM-1300

B-cell malignancies

Research Group

Novel Target

 

Target ID In vitro
Assays
Hit ID In vivo PoC
/ Lead id
ADMET / PK
Optimización
Preclinical Clinical
 
   
   
 
     
     
     
     
       
Partners
Licensed
IP

     
Undisclosed Undisclosed in-process
    in-process
Undisclosed Undisclosed in-process
Undisclosed   in-process
ok   in-process
    in-process
    in-process
     
 


 

Licensed Products in PreClinical & Clinical Phases
Click for more info Project Teaser


Indication
VTX-801 Acute intermit-
ent Porphyria

Research Group

CM-Mesh Heart Failure

Research Group

EDA vaccine Cervical
Cancer

Research Group

a5-IFN Manufacturing
RHct-1 * Acute kidney injure
AAV-PBGD * Acute intermittent Porphyria
CM-144 * Scleroderma

 

R&D Preclinical
Phase I Phase II Phase III
     
     
     
 
 
 
 
Licensed
IP


Vivet
Viscofan
Formune
BioTechpharma
Digna Biotech
Uniqure
Digna Biotech

 

* Terminated


 

Diagnostics

Click for more info Project Teaser


Indication
C4 activation fragment Lung Cancer
BM Panel Heart Failure

Research Group

Biomarker
identification
Analytical
Validation
Retrospective Clinical
Validation
Protrospective Clinical
Validation
Regulation
Process
Clinical
Utility
   
   
Partners
Licensed
IP

ok